U.S. markets closed
  • S&P 500

    4,127.83
    -35.46 (-0.85%)
     
  • Dow 30

    34,060.66
    -267.13 (-0.78%)
     
  • Nasdaq

    13,303.64
    -75.41 (-0.56%)
     
  • Russell 2000

    2,210.88
    -16.24 (-0.73%)
     
  • Crude Oil

    65.31
    -0.18 (-0.27%)
     
  • Gold

    1,869.80
    +1.80 (+0.10%)
     
  • Silver

    28.26
    -0.07 (-0.26%)
     
  • EUR/USD

    1.2228
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6420
    +0.0020 (+0.12%)
     
  • GBP/USD

    1.4191
    +0.0004 (+0.03%)
     
  • USD/JPY

    108.8490
    -0.0410 (-0.04%)
     
  • BTC-USD

    42,648.95
    -994.69 (-2.28%)
     
  • CMC Crypto 200

    1,206.81
    -46.33 (-3.70%)
     
  • FTSE 100

    7,034.24
    +1.39 (+0.02%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

Can You Imagine How Jubilant Travere Therapeutics' (NASDAQ:TVTX) Shareholders Feel About Its 112% Share Price Gain?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can see its share price rise well over 100%. Long term Travere Therapeutics, Inc. (NASDAQ:TVTX) shareholders would be well aware of this, since the stock is up 112% in five years. On top of that, the share price is up 25% in about a quarter. But this move may well have been assisted by the reasonably buoyant market (up 15% in 90 days).

Check out our latest analysis for Travere Therapeutics

Travere Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

For the last half decade, Travere Therapeutics can boast revenue growth at a rate of 12% per year. That's a fairly respectable growth rate. Broadly speaking, this solid progress may well be reflected by the healthy share price gain of 16% per year over five years. Given that the business has made good progress on the top line, it would be worth taking a look at the growth trend. Accelerating growth can be a sign of an inflection point - and could indicate profits lie ahead. Worth watching 100%

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

We're pleased to report that Travere Therapeutics shareholders have received a total shareholder return of 79% over one year. That's better than the annualised return of 16% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 4 warning signs for Travere Therapeutics you should be aware of.

Of course Travere Therapeutics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.